Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2082-2088

  Aldeyab, Mamoon A ^a   Harbarth, Stephan ^b   Vernaz, Nathalie ^b   Kearney, Mary P ^c   Scott, Michael G ^c   Funston, Chris ^c   Savage, Karen ^c   Kelly, Denise ^d   Aldiab, Motasem A ^e   McElnay, James C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^d Newtownabbey BT37 9RH   (United Kingdom)

^e GERMAN JORDANIAN UNIVERSITY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CARBAPENEM; CEPHALOSPORIN; CHLORHEXIDINE; GLYCOPEPTIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; LINCOSAMIDE; MACROLIDE; NITROFURAN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TRIMETHOPRIM; TRIMETHOPRIM DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; CORRELATION ANALYSIS; DRUG USE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MORBIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; TIME SERIES ANALYSIS; UNITED KINGDOM;

AGED; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HISTAMINE H2 ANTAGONISTS; HOSPITALS, TEACHING; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFECTION CONTROL; NORTHERN IRELAND;

EID: 66149143508     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01214-08     Document Type: Article

References (35)

1. Akhtar, A. J., and M. Shaheen. 2007. Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J. Natl. Med. Assoc. 99:500-504. (Pubitemid 46752728)
2. Aldeyab, M. A., D. L. Monnet, J. M. López-Lozano, C. M. Hughes, M. G. Scott, M. P. Kearney, F. A. Magee, and J. C. McElnay. 2008. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J. Antimicrob. Chemother. 62:593-600.
3. Al-Eidan, F. A., J. C. McElnay, M. G. Scott, and M. P. Kearney. 2000. Clostridium difficile-associated diarrhoea in hospitalised patients. J. Clin. Pharm. Ther. 25:101-109. (Pubitemid 30326409)
4. Apisarnthanarak, A., J. E. Zack, J. L. Mayfield, J. Freeman, W. M. Dunne, J. R. Little, L. M. Mundy, and V. J. Fraser. 2004. Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile. Clin. Infect. Dis. 39:601-602. (Pubitemid 39120946)
5. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
6. Baxter, R., G. T. Ray, and B. H. Fireman. 2008. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect. Control Hosp. Epidemiol. 29:44-50.
7. Braegger, C. P., and D. Nadal. 1994. Clarithromycin and pseudomembranous enterocolitis. Lancet 343:241-242. (Pubitemid 24031668)
8. Cadle, R. M., M. D. Mansouri, N. Logan, D. R. Kudva, and D. M. Musher. 2007. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am. J. Health Syst. Pharm. 64:2359-2363. (Pubitemid 350174708)
9. Dial, S., K. Alrasadi, C. Manoukian, A. Huang, and D. Menzies. 2004. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 17:33-38. (Pubitemid 38925116)
10. Dial, S., J. A. Delaney, A. N. Barkun, and S. Suissa. 2005. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294:2989-2995. (Pubitemid 41817660)
11. Gerding, D. N., C. A. Muto, and R. C. Owens, Jr. 2008. Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1):S43-S49.
12. Guyot, A., M. D. Rawlins, and S. P. Barrett. 2000. Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly. J. Antimicrob. Chemother. 46:642-643.
13. Harris, A. D., E. Lautenbach, and E. Perencevich. 2005. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin. Infect. Dis. 41:77-82. (Pubitemid 40863748)
14. Helfenstein, U. 1996. Box-Jenkins modelling in medical research. Stat. Methods Med. Res. 5:3-22. (Pubitemid 126550435)
15. Kazakova, S. V., K. Ware, B. Baughman, O. Bilukha, A. Paradis, S. Sears, A. Thompson, B. Jensen, L. Wiggs, J. Bessette, J. Martin, J. Clukey, K. Gensheimer, G. Killgore, and L. C. McDonald. 2006. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch. Intern. Med. 166:2518-2524.
16. Lewis, S. J., and K. W. Heaton. 1997. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol. 32:920-924. (Pubitemid 27382038)
17. Long, S., L. Fenelon, S. Fitzgerald, N. Nolan, K. Burns, M. Hannan, L. Kyne, S. Fanning, and D. Drudy. 2007. First isolation and report of clusters of Clostridium difficile PCR 027 cases in Ireland. Euro Surveill. 12:E070426.3.
18. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. René, Y. Monczak, and A. Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449. (Pubitemid 41770165)
19. McCusker, M. E., A. D. Harris, E. Perencevich, and M. C. Roghmann. 2003. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis. 9:730-733. (Pubitemid 36676373)
20. McFarland, L. V., J. E. Clarridge, H. W. Beneda, and G. J. Raugi. 2007. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin. Infect. Dis. 45:1141-1151. (Pubitemid 47580312)
21. McFarland, L. V. 2008. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 5:40-48.
22. McGowan, J. E., Jr. 1983. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev. Infect. Dis. 5:1033-1048.
23. McMaster-Baxter, N. L., and D. M. Musher. 2007. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 27:1029-1039. (Pubitemid 46986690)
24. Muto, C. A., M. Pokrywka, K. Shutt, A. B. Mendelsohn, K. Nouri, K. Posey, T. Roberts, K. Croyle, S. Krystofiak, S. Patel-Brown, A. W. Pasculle, D. L. Paterson, M. Saul, and L. H. Harrison. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26:273-280. (Pubitemid 40445086)
25. Owens, R. C., Jr., C. J. Donskey, R. P. Gaynes, V. G. Loo, and C. A. Muto. 2008. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1):S19-S31.
26. Pépin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P. Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V. Primeau, M. Nguyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the pre-dominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260. (Pubitemid 41532667)
27. Samore, M. H., L. Venkataraman, P. C. DeGirolami, M. M. Merrigan, S. Johnson, D. N. Gerding, Y. Carmeli, and S. Harbarth. 2006. Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure. Microb. Drug Resist. 12:23-28.
28. Schwaber, M. J., A. Simhon, C. Block, V. Roval, N. Ferderber, and M. Shapiro. 2000. Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 19:9-15. (Pubitemid 30093375)
29. Shardell, M., A. D. Harris, S. S. El-Kamary, J. P. Furuno, R. R. Miller, and E. N. Perencevich. 2007. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin. Infect. Dis. 45:901-907. (Pubitemid 47580386)
30. Starr, J. M., H. Martin, J. McCoubrey, G. Gibson, and I. R. Poxton. 2003. Risk factors for Clostridium difficile colonisation and toxin production. Age Ageing 32:657-660. (Pubitemid 37461575)
31. Thomas, C., M. Stevenson, and T. V. Riley. 2003. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhea: a systematic review. J. Antimicrob. Chemother. 51:1339-1350. (Pubitemid 36748921)
32. Thompson, I. 2008. Clostridium difficile-associated disease: update and focus on non-antibiotic strategies. Age Ageing 37:14-18.
33. Vernaz, N., H. Sax, D. Pittet, P. Bonnabry, J. Schrenzel, and S. Harbarth. 2008. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J. Antimicrob. Chemother. 62:601-607.
34. Vonberg, R. P., E. J. Kuijper, M. H. Wilcox, F. Barbut, P. Tüll, P. Gastmeier, European C difficile-Infection Control Group, European Center for Disease Prevention and Control (ECDC), P. J. van den Broek, A. Colville, B. Coignard, T. Daha, S. Debast, B. I. Duerden, S. van den Hof, T. van der Kooi, H. J. Maarleveld, E. Nagy, D. W. Notermans, J. O'Driscoll, B. Patel, S. Stone, and C. Wiuff. 2008. Infection control measures to limit the spread of Clostridium difficile. Clin. Microbiol. Infect. 14(Suppl. 5):2-20.
35. World Health Organization. 2002. Collaborating Center for Drug Statistics Methodology. Guidelines for ATC classifications and DDDs assignment. World Health Organization Collaborating Center, Oslo, Norway.